Navigation Links
New role for Tamoxifen in saving high-risk breast cancer patients
Date:8/7/2013

The global study was led by University of Melbourne and the Peter MacCallum Cancer Centre and published in the Journal of Clinical Oncology today.

The study involved about 2,500 women from Europe, North America and Australia who have inherited mutations in BRCA1 or BRCA2, the breast cancer susceptibility genes, and who had been diagnosed with breast cancer. About one-third of these women were placed on tamoxifen.

Tamoxifen has been used for decades to treat breast cancer and has recently been shown to prevent breast cancers in many women.

Until now, there has been limited information about whether it reduces breast cancer risk for women who are at the very highest level of risk with BRCA1 or BRCA2.

Lead author, Professor Kelly-Anne Phillips says this study, the largest to date, suggests that it could work for these high-risk women by halving their breast cancer risk.

"In the past, the only way of reducing breast cancer risk for these high-risk women was to do invasive surgery to remove their breasts and/or ovaries. For women who choose not to undergo such surgery, or who would prefer to delay surgery until they are older, tamoxifen could now be a viable alternative."

Such was the case for US actress Angelina Jolie who was found to carry a mutation in one of these genes.

Previous research led by Professor Phillips revealed that only 1 in 5 Australian women with a mutation in BRCA1 or BRCA2 choose to undergo bilateral mastectomy to prevent cancer.

Professor John Hopper, co-author from the School of Population and Global Health at the University of Melbourne, says "In light of our findings, it is clear that women who have a mutation in BRCA1 or BRCA2 should review their management plan with their specialist and re-discuss the options available to them to lower that risk."

This important finding has come from more than 20 years of research involving breast cancer families
'/>"/>

Contact: Anne Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Possible therapy for tamoxifen resistant breast cancer identified
2. New finding gives clues for overcoming tamoxifen-resistant breast cancer
3. 10 Years of Tamoxifen Better Than 5: Study
4. Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
5. Ability to metabolize tamoxifen affects breast cancer outcomes, Mayo Clinic-led study confirms
6. Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
7. Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
8. Doubling Time on Tamoxifen Cuts Odds for Breast Cancers Return: Study
9. Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
10. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
11. National poll: Low cost, lifesaving services missing from most older patients health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 With a growing number of ... Worldwide indicates that international political instability and terrorism top ... survey by Clements, a global insurance provider with 68 ... their country of citizenship, also found strong concern but ... health care insurance overseas . , Asked to choose ...
(Date:4/21/2015)... Pharmacy point of sale software provider ... Cooperative trade show, to be held April 30 through ... Management Solutions recently became an approved vendor with the ... of Sales and Marketing. Gross says that IPC hosts ... in the country -- and this new partnership will ...
(Date:4/21/2015)... Ramon, CA (PRWEB) April 21, 2015 ... announced Linda Burnes Bolton, DrPH, RN, FAAN, will keynote ... Transformation - in Long Beach, CA on October 26, ... President of the American Organization of Nurse Executives (AONE) ... As past president of the American Academy of Nursing ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 ... solutions for biopharmaceutical development, today announced that the ... the University of Ottawa has acquired a Freeslate ... Screening Pressure Reactor (SPR) to accelerate current ... High-Throughput Experimentation Facility where they will be available to ...
(Date:4/21/2015)... April 21, 2015 “The warm summer season ... every mother want to look younger than her age? ... first line of defense. Signs of premature aging ... evidence of too much time spent in the sun without ... to cover up. The dangers of UV rays can ...
Breaking Medicine News(10 mins):Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 2Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 3Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 3Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2
... 18, 2007) New research published in the December ... Surgeons shows that outcomes of high-risk cancer operations in ... and published survival statistics, which may lead to unrealistic ... elderly. With this limited information, elderly patients and their ...
... Offer Relief from Menopausal Symptoms, ST. LOUIS, Dec. ... years, new research demonstrates that soy isoflavones may offer,them ... for,approximately 25 percent of the total female population in ... generation enter their early,forties, an unprecedented number of women ...
... Cyberonics, Inc. (Nasdaq:,CYBX) announced that effective December ... with Ethicon Endo-Surgery granting exclusive rights to,the company,s ... (VNS) for the treatment of obesity and two ... Ethicon Endo-Surgery has agreed to pay Cyberonics a ...
... CHAPEL HILL, N.C., Dec. 18 Many large ... to maintain ever-expanding,product portfolio. These alliances are developed ... pharmaceutical companies use,in-licensing deals to tap into expertise ... much needed, capital, development expertise, and market,insight to ...
... 18 Despite all the scientific,advancements in drug ... trip from the lab to the marketplace. To ... best-in-class pharmaceutical companies have learned,to inject commercial insights ... from Best Practices, LLC., "It,s clear early ...
... Mellor is one of,more than 400,000 people in the ... It,s, a debilitating disease that causes,paralysis, blindness, incontinence and ... Mellor, the founder of the Accelerated,Cure Project for Multiple ... raising the funds he needs to scratch "Develop a ...
Cached Medicine News:Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2Health News:News Flash on Hot Flashes: Soy Can Turn Down the Heat 2Health News:Cyberonics Licenses Obesity-Related Patents 2Health News:Cyberonics Licenses Obesity-Related Patents 3Health News:Developing Excellence in Alliance 2Health News:Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3
(Date:4/20/2015)... , April 21, 2015  Following is the daily ... LIFESAVING MEDICINE Profile ... important medicines — insulin —became available for general use ... of people suffering from diabetes. Insulin is a hormone ... processing of carbohydrates in the human body. It was ...
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... ALPHARETTA, Ga. , April 20, 2015  Halyard Health ... discussing financial results and business highlights for the first quarter ... company will issue a news release detailing first quarter results ... conference call will be hosted by Robert Abernathy , ... Chief Financial Officer. To join the live conference ...
Breaking Medicine Technology:U.S. Census Bureau Daily Feature for April 21 2Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Halyard Health Inc. To Webcast Conference Call Discussing First Quarter 2015 Financial Results 2
... Pompe Patients May Be Amenable to Chaperone ... ... Amicus Therapeutics, a,biopharmaceutical company developing small-molecule, orally administered,pharmacological chaperones for ... present positive results from an ex,vivo response study and three Phase ...
... Raven,biotechnologies, inc., a privately held company focused on ... for cancer,today announced that it has initiated a ... in combination with gemcitabine in the treatment of,patients ... Pancreatic Cancer Study will be conducted at approximately,20 ...
Cached Medicine Technology:Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 2Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 3Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 4Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 2Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 3
... The SG210D combines a slab gel dryer ... convenient gel drying without any hardware setup. The ... fixed in acetic acid, protein/agarose gels, and multiple ... in 60 minutes or less. , Completely ...
Inquire...
... system, Hoefers Easy Breeze can dry as many as ... Mini-Gels (8 x 10 cm) at a time. , ... drying oven, a specially designed loading platform, and two ... no awkward connections., The Gel Frame is largely responsible ...
... HydroTech™ gel drying system, 220-240 V, includes Model ... The Model 583 gel dryer is a vacuum-based ... x 45 cm with variable temperature control and ... a water-based vacuum pump used for pulling vacuum ...
Medicine Products: